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Mono- and bi-cyclic 1,3-diazetidin-2-ones (aza-â-lactams) are synthesised and evaluated as non-natural
analogues of â-lactams. The aza-â-lactams are designed on the principle that their reaction with active
site serine hydroxy will form a carbamoyl–enzyme intermediate that is sluggish to hydrolysis. The
synthesis of racemic mono- and bi-cyclic aza-â-lactams is carried out starting from pyrimidinone 18
which is transformed to the densely functionalised substrate 20. The chemical reactivity of tricarbonyl
20 for selective functional group manipulation was first assessed and then it was transformed to amino
alcohol 24. Cyclisation of 24 affords aza-carbapenams and its homologation followed by aldol cyclisation
provides access to aza-carbacephams. The X-ray structures of aza-carbapenam 35 and aza-carbacepham
42 suggest that the structural requirements for biological activity in â-lactams are fulfilled. An unexpected
ozonolysis product, phenol 52 resolves spontaneously during crystallisation and its crystal structure was
also determined. The biological activity of the novel mono- and bi-cyclic aza-â-lactams was evaluated
with potent gram-positive bacterial strain, Bacillus subtilis and compared with â-lactam antibiotics,
ampicillin and penicillin G. Of the 19 aza-â-lactams tested, eight compounds show inhibition better
than the standards while another eight are of comparable activity. This study shows that aza-â-lactams
represent a novel and non-natural lead towards serine peptidase inhibitors.
1 Introduction
The b-lactam antibiotics have been in widespread use as chemo-
therapeutic agents to treat diverse bacterial infections and
microbial diseases.1 Despite the fact that there are about 150 b-
lactam antibiotics in the market today, the threat that microbes
are able to neutralise them is a major and growing concern to
medicinal chemists and clinicians.2 One of the reasons cited for
the spread of antibiotic resistance is the lack of diversity in the
chemical structures of b-lactam drugs. The b-lactam ring is the
common moiety in penicillins, cephalosporins, thienamycins
and related antimicrobial agents.3 These antibiotics are close
structural analogues of naturally occurring b-lactams and this
could be one of the reasons that microbes in the air and
soil have found ways to counter them.4 The extensive use of
classical b-lactam antibiotics in medicine has given rise to
an increasing number of resistant bacterial strains through
mutation and b-lactamase gene transfer. In recent years there
has been a keen interest in the design, synthesis and biological
testing of novel structural skeletons which will target the
penicillin binding proteins (PBPs) and also overcome the
defense mechanisms of bacteria. Non-traditional b-lactams
are a possible solution to the problem of bacterial resistance.
These compounds are non-natural analogues of penicillins and
cephalosporins that contain a different four- or five-membered
heterocycle in place of the usual 2-azetidin-1-one ring. Several
research groups have investigated the synthesis and biological
effects of such compounds to inhibit the b-lactamases, and these
efforts have been summarised in an excellent review.5
The g-lactam analogues 1–3 (Fig. 1), synthesised by Baldwin
and co-workers,6 exhibit weak antibacterial activity against
both gram-positive and gram-negative organisms. Mono- and
bi-cyclic 1,2-diazetidin-3-ones, such as 4 and 5 were found
to be ineffective against representative strains of bacteria
(MIC > 128 m) but the sulfonyl derivative 6 displayed some Fig. 1 Structures of some non-traditional b-lactam analogues
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antifungal activity.7 Among the pyrazolidinone containing
compounds the carbapenem analogue 7, prepared by the Eli
Lilly group,8 showed good binding to bacterial PBPs and
exhibited in vitro and in vivo antibacterial properties at use-
ful levels. Bicyclic imidazolidinones 8–10 were synthesised
by a Lossen rearrangement on clinically active penicillins
and cephalosporins and tested as antibacterial agents and b-
lactamase inhibitors. Although imidazolidinones 8–10 were
devoid of antimicrobial activity, the sulfone 11 showed 30–60%
b-lactamase inhibition at 1 m concentration.9
In this paper we report the synthesis of molecules that belong
to the 1,3-diazetidin-2-one (aza-b-lactam) structural type as
non-natural analogues of b-lactams.10 The X-ray crystal
structure and bioassays on selected compounds suggest
that aza-b-lactams are potential serine peptidase inhibitors.
The rationale for the design of aza-b-lactams as transpep-
tidase and b-lactamase inhibitors has been proposed earlier
by us.11 Thus, attack of active site Ser-OH on the aza-b-lactam
nucleus 13 should lead to carbamoyl–enzyme intermediate
16 which is stabilised by partial amino-donation (Fig. 2). The
resonance stabilisation in intermediate 17 will retard the
normal deacylation pathway and provide hydrolytic stability
to aza-b-lactams thereby making them less susceptible to the
destructive action of b-lactamases. Such a stabilisation is not
available on the acyl–enzyme intermediate 14 derived from
the natural b-lactams 12, and its hydrolysis to inactive 15
renders the antibiotic ineffective. Ghosez and co-workers
evaluated the 1,3-imidazolidinones 8–11 for a similar reason 9
but found the molecules to be inactive, presumably because the
topological changes from a four- to a five-membered hetero-
cycle are too severe for effective drug–receptor recognition.2c
The aza-b-lactam analogues 13 are closer structural mimics of
b-lactams and also benefit from resonance stabilisation in the
carbamoyl–PBP intermediate. Moreover, being non-natural
they should be less vulnerable to the defence strategies of
microorganisms.4
Fig. 2 Mechanism for the inactivation of PBP enzyme by aza-b-
lactams
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2 Results and discussion
2.1 Synthesis
Photolysis of 1-phenyl-4,6-dimethylpyrimidin-2-one 18
afforded 3-phenyl-4,6-dimethyl-2-oxo-1,3-diazabicyclo[2.2.0]-
hex-5-ene 19 in 42% yield after silica gel chromatography.12
Ozonolysis and reductive work-up with Me2S provided an
easily separable >4 :1 mixture of aldehyde 20 and acetal 21
(Scheme 1). The isolated yield of acetal 21 was significantly
improved (1 :1) when the ozonide was treated with Et3N
13
instead of Me2S. Of the four possible diastereomers of 21, three
were isolated in pure form and characterised by their acetal
C]H singlets at d 5.85, 5.43 and 4.98. The three carbonyl groups
in 20 are chemically distinct and these were identified by their
different IR stretching frequencies at 1807 cm21 (urea), 1742
cm21 (acetamide) and 1690 cm21 (aldehyde). Heterocycle 20 is
a densely functionalised aza-b-lactam and serves a useful syn-
thon for the synthesis of racemic aza-b-lactams.11c Further-
more, differences in the chemical reactivity of aldehyde, amide
and diazetidinone groups in 20 should permit selective trans-
formations for elaboration to the target substrates.
The first target was the bicyclic aza-carbapenam 25 (Scheme
2). Treatment of tricarbonyl 20 with stabilised phosphorane
or phosphonate reagent [Ph3P]]CH]CO2Et, (EtO)2P(O)-
CH2CO2Et–NaH] afforded the trans-ester 22 after condens-
ation with the aldehyde group. The reaction was not com-
plicated by competition from the amide and urea carbonyl
groups. The unsaturated ester was hydrogenated to 23 and
reduced with LiAlH4 at 0 8C. Under the standard ester
group reduction conditions, the N-acetyl group was cleaved
off to afford amino alcohol 24 directly. The concomitant
deacetylation proved beneficial in the subsequent step.
Exposure of amino alcohol 24 to Mitsunobu conditions 14
cleanly furnished the desired bicyclic aza-b-lactam 25, an
analogue of carbapenam antibiotics 15 but devoid of the crucial
carboxy group at C3 (penicillin numbering). The structure of
25 was established by 1H, 13C, 1H–1H COSY NMR,16 IR spectra
and also by comparison with a related structure.17 In 25, the
diazetidinone carbonyl appears at 1774 cm21 and the N]CH2
diastereotopic protons exhibit well separated multiplets at
d 3.62–3.51 and 2.82–2.65. The complex couplings between
the CH2 protons were revealed in the 2D COSY spectrum.
The aza-carbapenam 25 is the first compound in the bicyclic
aza-b-lactam series and an examination of its X-ray crystal
structure seemed desirable. However, attempts to crystallise
the viscous liquid were unsuccessful and attention shifted there-
fore to the 4-bromophenyl derivative 26. The same protocol
was followed for the synthesis of 26 except that the hydro-
genation was carried out with Pt2O instead of Pd/C
18 since the
latter catalyst leads to hydrogenolysis of the bromophenyl
group. Unfortunately, the 4-bromophenyl carbapenam 26 too
did not yield single crystals suitable for X-ray analysis despite
repeated attempts at recrystallisation from a number of
solvents.
Scheme 1 Reagents and conditions: i, hv, l > 300 nm, PhH, 3 h, 46%; ii,
O3, CH2Cl2, 278 8C; iii, Me2S (69%) or Et3N
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Based on the synthesis of aza-carbapenam 25 from hetero-
cycle 20, the synthesis of aza-carbacepham 28 from the
homologated aldehyde 27 appeared to be a viable extension
and so the synthesis of this aldehyde became our next target.
Treatment of aldehyde 20 with unstabilised Wittig phos-
phoranes, Ph3P]]CH2 or Ph3P]]CH]OMe
19 in THF afforded a
complex mixture of products whose characterisation suggested
that the diazetidinone ring was cleaved during the reaction.
Related efforts at homologation of aldehyde 20 with Corey–
Chaykovsky reagents, Me2S]]CH2 and Me2S(O)]]CH2 gave
epoxide 29 (Scheme 3) with concomitant loss of acetyl group.
Attempted isomerisation of the epoxide to the aldehyde 27 was
unsuccessful.20 Though the above experiments did not advance
the synthesis towards the target molecule 28, they provided
a better understanding of the chemical reactivity of the 1,3-
diazetidin-2-one ring, a heterocyclic system that has been
synthesised earlier 21 but its reactions not well-studied. The
above studies suggest that: (i) strongly nucleophilic reagents
Scheme 2 Reagents and conditions: i, Ph3P]]CHCO2Et, PhH, rt, 1 h,
80%; ii, H2, 10% Pd/C, EtOAc, rt, 4 h, 99%; iii, LiAlH4, Et2O, 0 8C, 1 h,
68%; iv, Ph3P, EtO2C]N]]N]CO2Et, PhH, rt, 1 h, 84%
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Scheme 3 Reagents and conditions: i, Me3S
1I2, NaH, Me2S]]O, 210 to
0 8C, 40 min, 30%; ii, LiAlH4, Et2O, 0 8C, 1 h, 29%; iii, NaBH4, MeOH,
0 8C, 1 h, 44%; iv, Ph3P, CBr4, CH2Cl2, 0 8C, 10 min, 35%; v, Ph3P]]CH2
or Ph3P]]CH]OMe, THF, 0 8C
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(Ph3P]]CH2, Ph3P]]CH]OMe) react indiscriminately and
completely destroy the sensitive tricarbonyl molecule 20; (ii)
moderately nucleophilic reagents [LiAlH4, Me2S]]CH2, Me2S-
(O)]]CH2] react at the aldehyde group but also result in
simultaneous deacetylation at the amide group, and; (iii)
weakly nucleophilic reagents [Ph3P]]CH]CO2Et, (EtO)2P(O)-
CH2CO2Et–NaH] react at the aldehyde group selectively.
The order of carbonyl reactivity in 20, that is diazetidin-
one < amide < aldehyde, was further assessed by treatment of
20 with the weaker NaBH4 reducing agent and milder dibromo-
Wittig conditions.22 A mixture of hydroxy amide 31 and
isoclavam 32 in the former reaction and the dibromo olefin
33 in the latter case were isolated. The above observation,
namely that the diazetidinone ring is the least reactive and the
aldehyde group is the most reactive in heterocycle 20 guided
further synthetic planning in the project.
The homologation of amino alcohol 24 was attempted next
with a view to synthesise aza-carbacepham 28. Oxidation of
amino alcohol 24 with PCC afforded a product which was
devoid of the expected downfield C]H resonance in the NMR
spectrum and the aldehyde carbonyl stretch in the IR spectrum.
The spontaneous cyclisation of the intermediate amino alde-
hyde afforded aminal 34 (Scheme 4) as a single diastereomer
after PCC oxidation.23 The stereochemistry of 34 was assigned
by its 2D NOESY spectrum in which the broad OH signal
at d 2.84 showed an NOE with the Me singlet at d 1.85 and
additionally, irradiation of the methine NCH resonance at
d 5.32 did not show enhancement of the methyl signal.
The observed stereochemistry in the product results from
cyclisation under equilibrium control in the acidic environ-
ment of PCC to afford the more stable exo oriented hydroxy
group. Standard O-benzoylation (PhCOCl–pyridine) of the
hydroxy amide 34 yielded the benzoyl derivative 35. Fortu-
nately, this benzoate afforded X-ray quality crystals and its
crystal structure is discussed in the next section.
The bicyclic aza-carbapenams 25 and 34 lack the crucial
carboxy group for recognition and binding between the b-
lactam and the receptor protein.2d,24 In order to fulfill the
structural requirements for biological activity, the synthesis of
bicyclic aza-b-lactams with a carboxy group was targeted.
From the above results it is clear that the urea NH reacts
intramolecularly with electrophilic groups and that it should be
suitably protected. The derivatisation of the urea NH was
planned in such a way that it protects the free NH and also
provides a functionality for aldol cyclisation that later becomes
a part of the product molecule.25 Thus, amino alcohol 24 was
transformed to aldehyde ester 39, which was identified as an
advanced precursor for the synthesis of aza-carbacephams with
a carboxy group at C4 (cephalosporin numbering).26
In the event, selective O-protection of amino alcohol 24
with TBDMSCl–Et3N produced the O-TBDMS ether 36.
The diazetidinone NH in 36 was deprotonated with NaH and
the anion treated with BrCH2CO2Et in THF to afford the N-
alkylated ester 37 (Scheme 5). The homologation with acetic
ester residue protects the reactive urea NH and also installs the
functionalised carbon fragment required to prepare the target
compound. Desilylation of 37 with TBAF produced alcohol
ester 38, which on oxidation with PCC in CH2Cl2 furnished
aldehyde ester 39 in 55% overall yield. Intramolecular aldol
Scheme 4 Reagents and conditions: i, PCC, CH2Cl2, 0 8C to rt, 2 h,
65%; ii, PhCOCl, pyridine, CH2Cl2, 0 8C to rt, 2 h, 62%
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reaction of 39 with ButOK or NaH and dehydration of the
intermediate hydroxy ester at 0 8C for 45 min furnished the
desired aza-carbacephem 40. The intermediate aldol product,
b-hydroxy ester 42 was obtained as a single diastereomer when
the reaction was conducted at 0 8C for a shorter duration of
20 min (Scheme 6). The stereospecificity in the aldol cyclisation
to afford the anti product exclusively is ascribed to the transi-
tion state 41 in which the aldehyde carbonyl group is axially
oriented for attack by the ester enolate. The stereochemistry
of the aldol product was assigned based on the 2D NOESY
spectrum 16 and confirmed by the single crystal X-ray analysis
of b-hydroxy ester 42.
The synthesis of related aza-carbacephams 44 and 46 from
mesylate ester 43 and diester 45 (Scheme 7), respectively, was
attempted next. When mesylate ester 43 and diester 45 were
subjected to cyclisation under basic conditions, the expected
Scheme 5 Reagents and conditions: i, ButMe2SiCl, Et3N, DMAP (cat.),
0 8C, 1 h, 90%; ii, NaH, BrCH2CO2Et, THF, 0 8C to rt, 2 h, 98%; iii,
Bun4NF, THF, 0 8C, 1 h, 82%; iv, PCC, CH2Cl2, 0 8C to rt, 2 h, 76%; v,
NaH, THF, 0 8C, 45 min, 35%
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Scheme 6 Reagents and conditions: i, NaH, THF, 0 8C, 20 min, 60%
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Scheme 7 Reagents and conditions: i, MeSO2Cl, Et3N, CH2Cl2, 0 8C,
1 h, 95%; ii, NaH or ButOK, THF; iii, PDC, DMF, rt, 8 h, 94%; iv,
CH2N2 (excess), 0 8C, 80%
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products were not obtained. The failure of these cyclisations is
attributed to the lower electrophilicity of the mesylate and ester
groups when compared to the aldehyde for attack by the same
ester enolate, shown in 41. It is known that alkylation and
acylation are less facile than aldol condensation 19a,b and this
could be the reason for the failure of related cyclisations. In
view of these results, the synthesis of aza-carbacepham 44 was
planned by the reduction of carbacephem 40 and that of 46 by
the oxidation of hydroxy ester 42.
Hydrogenation of unsaturated ester 40 produced aza-
carbacepham 47 (Scheme 8) as a single stereoisomer with an
exo oriented ester group. The structure of 47 was confirmed by
its 2D 1H–1H NOESY spectrum.16 The presence of an NOE
between the OCH2 multiplet (d 4.25) and the quaternary methyl
singlet (d 1.71) and furthermore, the absence of an NOE
between the NCHCO2Et resonance (d 4.59) and the methyl
group confirmed the exo orientation of the ester group. The
observed stereochemistry in the product arises by the reduction
of 40 from the endo face exclusively. This stereospecificity
may be due to the fact that in the somewhat flat bicyclic
aza-carbacepham molecule (AM1 SN = 335–3408),11b the exo
oriented methyl group shields the convex face and directs
hydrogenation 18 from the less hindered concave face. As a
result, the carboxy group has the exo orientation of the natural
b-lactams.
Carbacephems 27 with a C3-hydroxy group have been identi-
fied as useful precursors for the synthesis of biologically active
carbacephems with various side-chains. For example, the 3-
methoxy- and 3-chloro-cephalosporins with a phenylglycine
side chain are orally active antimicrobial agents.28 The hydroxy
aza-carbacephem 48 appeared to be an accessible precursor for
such targets in the aza-b-lactam family. Attempted oxidation
of the secondary alcohol in b-hydroxy ester 42 under PCC,
PDC and Swern conditions did not yield the ketone product 46,
presumably because of the proximal electron withdrawing
ester and diazetidinone groups. However, oxidation with the
more powerful Jones reagent at 0 8C for 1 h produced a
1 :1 mixture of keto and enol isomers 46 and 48 (Scheme 9).
When the 1 :1 keto–enol mixture was left for 2 days at
room temperature, the solution contained the enol form pre-
dominantly (90 :10). This enriched mixture was immediately
methylated with diazomethane to afford the methyl enol ether
Scheme 8 Reagents and conditions: i, H2, 10% Pd/C, EtOAc, rt, 4 h,
86%
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Scheme 9 Reagents and conditions: i, 8  Jones reagent, 0 8C to rt, 2 h,
then rt, 2 days, 88%; ii, CH2N2 (excess), 0 8C, 63%
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49. The C3-oxygenated aza-carbacephems should serve as
advanced precursors for the synthesis of biologically active
aza-carbacephem analogues.
2.2 X-Ray crystallography
It has been shown by us that the Cambridge Structural Data-
base (CSD) 29 can be profitably utilised to obtain structural
parameters favourable for biological activity in the b-lactam
class of drug molecules.30 The motivation for the determination
of X-ray crystal structures of aza-b-lactams was thus three-
fold: (i) to confirm the chemical structure and the stereo-
chemistry of the molecules in this study; (ii) to compare the
structural parameters in aza-b-lactams with those found in b-
lactams, and; (iii) to examine the hydrogen bonding and crystal
packing motifs in this class of molecules. A search of the CSD
(Version 5.11, April 1996 update, 167 797 entries) for the aza-
b-lactam fragment 50 furnished five hits, all of which belong
to the 1,3-diazetidin-2,4-dione skeleton 51. The absence of
1,3-diazetidin-2-ones in the CSD suggested that a study of their
structural features should be interesting. The crystal structures
of benzoate 35, hydroxy ester 42 and phenolic alcohol 52 are
discussed in this section.
Benzoate 35. The benzoate was recrystallised from a mixture
of CH2Cl2 and hexane at room temperature to afford X-ray
quality crystals. The compound crystallises in the monoclinic
space group P21/c. The exo and cis stereochemistry of the
methyl and benzoate groups deduced from the NOE data on the
hydroxy precursor 34 are confirmed (Fig. 3). Based on the C]N
distance (r), the Woodward parameter (h) 31 and the sum of
angles at the N-atom (SN) values from the X-ray analysis, it is
evident that N1 is in a pyramidal environment with inhibited
N
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Fig. 3 Molecular structure of benzoate 35 showing ellipsoids at 50%
probability level
conjugation and that N3 is in maximum resonance with the
p-framework of the adjacent C]]O group. This is reflected in a
shorter C2]N3 bond [1.375(2) Å] compared to the C2]N1 bond
distance [1.438(2) Å] and by their SN values (SN3 = 359.998,
SN1 = 311.748). An h value of 0.601 Å and a C]N bond of
intermediate strength with hindered amide resonance suggest
that structural parameters favourable for antibiotic activity in
b-lactams 30 are found in aza-b-lactam 35. These observations
from the crystallographic data support some of the conclusions
derived from AM1 calculations,11b notably that N1 and N3
atoms are in chemically distinct environments and form C]N
bonds of different strengths. This could have a bearing on the
regioselectivity in the cleavage of the diazetidinone ring C]N
bond upon attack by the active site Ser-OH group and other
nucleophiles.
There are no strong hydrogen bonding groups (OH, NH2) in
35 and the structure is stabilised by the weaker C]H ? ? ? O,
C]H ? ? ? N and C]H ? ? ? p hydrogen bonds.32 The geometrical
parameters of some of these interactions are listed in Table 1.
â-Hydroxy ester 42. The compound was recrystallised from a
mixture of CH2Cl2 and hexane. The space group is P21/c and
there are two molecules, A and B, in the asymmetric unit that
have similar bond distances, angles and conformations. The
stereochemistry of the aldol product, b-hydroxy ester 42,
assigned from NOE experiments is confirmed from its X-ray
structure (Fig. 4). The quaternary methyl and the ester groups
are exo and cis to each other while the hydroxy group is on the
endo face and trans to the ester and methyl groups. The crystal
structure is stabilised by many strong (O]H ? ? ? O) and weak
(C]H ? ? ? O) hydrogen bonds, some of which are listed in Table
2. It may be noted that the C]H ? ? ? O hydrogen bonds in which
the donor C]H is acidic, that is activated by an ester group or
part of a phenyl C]H group, are shorter (d < 2.40 Å) than the
other C]H ? ? ? O bonds. This is in keeping with general trends
for C]H ? ? ? O hydrogen bonds.32 The overall patterns of inter-
actions that constitute the crystal structure are quite complex
and the details are not discussed here. The h and c (Cohen
distance) 33 values of the two molecules of hydroxy ester 42
(A: h = 0.33 Å, c = 4.35 Å; B: h = 0.36 Å, c = 4.35 Å) are in the
range favourable for biological activity.30
Phenolic alcohol 52. The synthesis of alcohol 31 detailed
Table 1 Geometrical parameters for X-ray structure of benzoate 35
Interaction
C(16)]H ? ? ? O(10)
C(20)]H ? ? ? O(12)
C(22)]H ? ? ? O(5)
C(23)]H ? ? ? O(10)
C(23)]H ? ? ? N(1)
d/Å
2.760
2.535
2.690
2.529
2.771
D/Å
3.659
3.370
3.632
3.422
3.703
q/8
140.20
133.21
145.04
139.19
144.16
Fig. 4 Molecular structure of the two molecules of ester 42 showing ellipsoids at 50% probability level
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in Scheme 3 was carried out in three steps: ozonolysis of
the alkene 19, reductive work-up with Me2S, and reduction
of the aldehyde 20 with NaBH4. We felt that an alternative
and shorter synthesis of alcohol 31 could be the reduction
of ozonide derived from alkene 19 with NaBH4 to obtain the
alcohol directly in a single pot (Scheme 10). Instead of the
expected alcohol, a different compound was isolated that con-
tained an additional oxygen atom based on its mass spectral
analysis.
The structure of this unexpected compound was unambigu-
ously determined as 52 by X-ray analysis. Though the exact
mechanism for the direct formation of 52 from 19 is not clear,
it is likely that some sort of electrophilic hydroxylation of the
phenyl group with ozone or the ozonide is involved.34 Recrystal-
lisation of racemic 52 from CH2Cl2 and hexane afforded single
crystals in the non-centrosymmetric and enantiomorphous
orthorhombic space group P212121. The phenomenon of
spontaneous resolution,35 that is the crystallisation of a racemic
molecule in separate enantiomorphous crystals, rather than
as a racemic (and centrosymmetric) crystal is still poorly
understood, despite its antiquity. It is known, however, that the
presence of phenolic and alcoholic OH groups in a molecule
tends to favour crystallisation in enantiomorphous space
groups.36 Spontaneous resolution is a related phenomenon and
in this case, the presence of both these types of OH groups
in the molecule could be the reason for its occurrence. The
packing of molecules in the crystal structure of 52 is shown in
Fig. 5. The phenolic OH is intramolecularly hydrogen bonded
to the alcoholic OH which in turn is hydrogen bonded to
the acetyl C]]O of a 21 screw-related molecule. Additionally,
the phenyl C]H is hydrogen bonded to the phenolic OH and
the hydroxymethyl C]H is bonded to the diazetidinone C]]O
of distinct 21-related molecules. Molecules translated along
[010] are connected by C]H ? ? ? O hydrogen bonds between the
phenol rings. The geometrical parameters of these interactions
are listed in Table 3.
2.3 Bioassay
The 1,3-diazetidinones described in the paper as well as other
related compounds synthesised in this study 37 were tested for
antibacterial activity against Bacillus subtilis, a gram-positive
bacterium of a highly potent and evolved species. The inhib-
ition of bacterial growth was studied in wells of microtitre
Scheme 10 Reagents and conditions: i, O3, CH2Cl2–MeOH, 278 8C; ii,
NaBH4, 0 8C, 1 h, 40%
N
N
O Me
Me
H N
N
O
Me
Me
O
CH2OH
OH
5219
i, ii
Table 2 Geometrical parameters for X-ray structure of b-hydroxy
ester 42
Interaction
O(11)]H ? ? ? O(5)
O(119)]H ? ? ? O(59)
C(6)]H ? ? ? O(5)
C(69)]H ? ? ? O(59)
C(89)]H ? ? ? O(119)
C(8)]H ? ? ? O(11)
C(9)]H ? ? ? O(139)
C(19)]H ? ? ? O(13)
C(209)]H ? ? ? O(11)
C(109)]H ? ? ? O(5)
C(10)]H ? ? ? O(59)
C(169)]H ? ? ? N(39)
C(169)]H ? ? ? O(13)
d/Å
1.839
1.851
2.289
2.377
2.557
2.549
2.471
2.356
2.350
2.847
2.542
2.977
2.473
D/Å
2.768
2.813
3.141
3.293
3.589
3.607
3.359
3.322
3.420
3.925
3.445
3.924
3.510
q/8
156.46
165.34
134.10
141.34
158.92
165.26
138.41
147.64
169.38
173.45
140.22
146.26
159.87
plates, the growth being monitored by measuring the turbidity
of the cultures with a microplate reader at 405 nm.38 An
enzyme-linked immunosorbent assay (ELISA) was used for
measuring the turbidity as optical density (OD) in yeast extract
peptone dextrose (YEPD) as the medium for bacterial growth.
The inhibition was measured against two standard b-lactam
drugs, ampicillin and penicillin G of known activity. The struc-
tures of the mono and bicyclic aza-b-lactams evaluated against
B. subtilis are shown in Fig. 6 with the percentage inhibition
at a concentration 330 mg ml21 being displayed in Fig. 7.
Examination of the biological activity data suggests that of
the 19 compounds tested, eight compounds (22, 26, 35, 47, 49,
53, 54, 57) show inhibition better than the standards (>40%),
eight compounds (21, 23, 24, 25, 34, 40, 55, 56) are comparable
to or slightly lower than the standards in their activity (20–
40%), while three compounds (19, 42, 58) show poor inhibition
(<20%). The p-bromophenylcarbapenam 26 exhibited excellent
activity and is the most active of all compounds evaluated,
showing >90% bacterial growth inhibition at 150 mg ml21 and
100% inhibition at 300 mg ml21 concentration (IC50 = 60 mg
ml21). The activity of carbapenam benzoate 35, whose X-ray
structure has been determined is quite good (80% inhibition)
and is better than the precursor hydroxy compounds 34 and 24.
While studying the effect of bicyclic skeleton and hydroxy
group on biological activity, Sheehan et al.23 found aminal 59
to be more potent than its acetate 60 and the open form 61. In
Fig. 5 Hydrogen bonding in the crystal structure of phenol 52. The
molecules have the R configuration in the crystal chosen for study.
N
S
OH
O
N
S
OAc
O N
S
O OHH
59 60 61
Table 3 Geometrical parameters for X-ray structure of phenolic alco-
hol 52
Interaction
O(18)]H ? ? ? O(7) a
O(7)]H ? ? ? O(17) b
C(8)]H ? ? ? O(5) c
C(13)]H ? ? ? O(18) d
C(11)]H ? ? ? O(18)
C(16)]H ? ? ? O(5)
d/Å
1.721
1.723
2.580
2.475
2.754
2.951
D/Å
2.681
2.694
3.626
3.364
3.691
3.960
q/8
164.04
168.58
162.12
138.52
144.65
155.09
a–d Represent interactions shown in Fig. 5. 
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Fig. 6 Chemical structures of aza-b-lactams chosen for biological screening: (a) parent molecules; (b) bromophenyl derivatives; (c) additional
compounds; (d) standard antibiotics
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(c)
34 35
2422
40
25
26
47 49
(a)
42
21 23
(b)
(d)
Penicillin G Ampicillin
53 54
55 56 57 58
this study, we find that the inhibition of B. subtilis is in the
order: benzoate 35 > acetate 57 > aminal 34 > open form 24.
In addition to the bioassay results on aza-b-lactams, it may be
noted that the diazetidinone carbonyl IR stretching frequency
of these molecules (see Experimental section) is in the range
favourable for active b-lactam antibiotics (1770–1800 cm21).39
While the above results show that mono- and bi-cyclic aza-
b-lactams inhibit bacterial growth, the exact mechanism
by which these molecules exert their antibacterial activity
cannot be deduced from the limited structure–activity data.
The comparison with ampicillin and penicillin G is to show
Fig. 7 Histogram for the percentage inhibition of Bacillus subtilis at a
concentration of 330 mg ml21 by the compounds shown in Fig. 6.
Notice that out of the 19 compounds tested, eight show inhibition
better than the standards.
that the novel skeleton is intrinsically active, even as it is
understood that the mode of action of aza-b-lactams could
be different from that of b-lactams.40 Likewise, the similarity
of the carbonyl stretching frequency between well-known b-
lactams and the newly synthesised aza-b-lactams suggests
that this structural parameter is in a favourable range. In sum-
mary, the bioassays though limited in scope are encouraging
enough to initiate further work on the biological activity and
mechanism of action of these molecules.
3 Conclusions
The aza-b-lactams discussed in this paper are non-natural
structural mimics of b-lactams derived from the isosteric
replacement of CH group by N-atom in the four-membered
heterocycle. The target molecules are synthesised by the photo-
chemical electrocyclisation of a pyrimidinone to afford the
1,3-diazetidin-2-one heterocycle. The chemical reactivity of
diazetidinones has been studied with a variety of synthetic
reagents for selective functional group manipulation. Mono-
and bi-cyclic aza-b-lactams have been synthesised in a few steps
with minimal use of protecting groups and in good overall
yields. Carbapenam analogues without the carboxy group at
C3 and carbacepham analogues with the carboxy group at C4
have been synthesised. The X-ray crystal structures of selected
compounds have been determined to confirm their molecular
structure and also to study the structural parameters that
influence biological activity in b-lactam antibiotics.
The biological activity has been assayed by measuring the
inhibition of bacterial growth in gram-positive strain, B. subti-
lis. A majority of the molecules tested show higher inhibition
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Table 4 Crystallographic details for aza-b-lactams 35, 42 and 52
Compound
Molecular formula
Crystal size/mm
Formula weight
Crystal system
Space group
Unit cell parameters/Å, 8
No. mols. in unit cell (Z)
Volume/Å3
Density (calc.)/mg m23
F(000)
Diffractometer used
Temperature/K
Absorption coeff./mm21
Collection range/8
Total reflections
Unique data measured
Goodness-of-fit on F 2
Final R indices [I > 2s(I)]
R indices (all data)
35
C19H18N2O3
0.10 × 0.20 × 0.25
322.35
Monoclinic
P21/c (No. 14)
a = 10.332(2)
b = 9.140(2)
c = 17.363(3)
b = 98.170(10)
4
1623.0(6)
1.319
680
Enraf Nonius
120
0.090
2.52 to 27.48
13 851
3708
1.045
0.0456
0.0565
42
C16H20N2O4
0.25 × 0.25 × 0.25
304.34
Monoclinic
P21/c (No. 14)
a = 9.715(3)
b = 20.211(6)
c = 15.923(7)
b = 90.92(3)
4
3126(2)
1.293
1296
Enraf Nonius
120
0.094
2.39 to 28.96
22 515
7702
0.754
0.0462
0.0903
52
C12H14N2O4
0.25 × 0.25 × 0.15
250.25
Orthorhombic
P212121 (No. 19)
a = 6.814(2)
b = 6.905(3)
c = 25.579(9)
4
1203.5(8)
1.381
528
Enraf Nonius
120
0.105
3.06 to 28.95
11 943
1798
0.885
0.0375
0.0434
than the well-known standard antibiotics, ampicillin and peni-
cillin G. Since this is an exploratory study on the antibacterial
activity of a novel skeleton, synthetic ease dictated that the
bioassays be carried out on racemic molecules. This raises the
interesting possibility of testing the biological activity of chiral
aza-b-lactams, which will naturally be higher than that found
for the racemic molecules. The present study suggests directions
for further work on a novel and non-natural class of serine
peptidase inhibitors.
Experimental
Synthesis
IR spectra were recorded on Jasco 5300 FT-spectrometer.
1H and 13C spectra were recorded as a solution in CDCl3 on
Bruker ACF 200 instrument at 200 and 50 MHz, respectively
and reported as dH and dC values. J Values are given in Hz.
Elemental analysis was performed on Perkin-Elmer 240C,
LRMS on JEOL JMS DX303 and HRMS on Micromass
VG70/70H instruments. Photolysis and ozonolysis were carried
out on the models available from Ace Glass and Welsbach.
Work up means drying of organic extracts with MgSO4,
solvent removal on rotary evaporator and concentration in
vacuo. All reactions were carried out using standard syringe-
septum techniques in an inert N2 atmosphere with magnetic
stirring. All reagents and solvents were dried and distilled prior
to use.41
Crystallography
The intensity data were collected on an Enraf Nonius FAST
area detector with no absorption correction. Mo-Ka (l =
0.710 73 Å) radiation was used in the w–2q scan mode. The
structures were solved by automatic direct methods (SHELXS
86) 42 and refined by full-matrix least-squares refinement
(SHELXL 93).43 H-atoms were refined isotropically. Normal-
ised H-atom distances (C]H 1.083 Å; O]H 0.983 Å) are used
in the hydrogen bond geometries detailed in Tables 1–3. The
crystallographic data for aza-b-lactams 35, 42 and 52 are
summarised in Table 4.
Full crystallographic details, excluding structure factor
tables, have been deposited at the Cambridge Crystallographic
Data Centre (CCDC). For details of the deposition scheme,
see ‘Instructions for Authors’, J. Chem. Soc., Perkin Trans. 1,
available via the RSC Web pages (http://www.rsc.org/authors).
Any request to the CCDC for this material should quote the full
literature citation and the reference number 207/230.
Version 5.11 (April 1996 update, 167 797 entries) of the
CSD 29 was used to search for fragment 50. No screens were
applied.
Bioassays
The yeast extract peptone dextrose (YEPD) medium was pre-
pared from the following: yeast extract 10 g, peptone 20 g, dex-
trose 5 g, double distilled water 1000 ml (pH 7). B. subtilis was
cultured in YEPD medium. Each well of the microtitre plate
was loaded with 25 ml of mid-log phase bacterial culture, YEPD
medium and the aza-b-lactam compounds at different concen-
trations in DMSO to a final volume of 150 ml and incubated at
30 8C. Triplicate readings were recorded for each concentration
and repeated twice. Every alternate well was kept empty to pre-
vent interference and cross-contamination. The change in
absorbance was monitored at 405 nm every 8 h up to 24 h. A
total of 125 ml of YEPD medium and DMSO (1–10 ml) inocu-
lated with 25 ml of mid log-phase culture of B. subtilis served
as control for the same concentration of the compound in
DMSO. The compounds were dissolved in DMSO such that
1 ml of the solution contained 10 mg of the compound. The
optical density (OD) values were determined by taking the
average of triplicate observations calculated by subtracting
the values of the first measurement from those at a specific
time. The percentage inhibition of bacterial growth was
calculated from the difference in OD after 16 h (mid-log
phase) using eqn. (1). In this way the IC50 (concentration
%inhibition =
ODcontrol 2 ODcompound
ODcontrol
× 100 (1)
for 50% inhibition) values for different aza-b-lactams were
determined.
3-Phenyl-4,6-dimethyl-2-oxo-1,3-diazabicyclo[2.2.0]hex-5-ene
19
A solution of pyrimidinone 18 (1.20 g, 6.0 mmol) in 350 cm3
of degassed benzene in a quartz vessel was irradiated with a
high pressure mercury lamp using a Pyrex filter for 3 h. The
solvent was removed in vacuo to provide a 1 :1 photostationary
mixture which upon purification by silica gel chromatography
(hexane to 10% EtOAc–hexane) gave pure alkene 19 (560 mg,
46%). The recovered starting material (~50%) was recycled.
Mp 62–64 8C; nmax/cm
21 3123, 3040, 2988, 1766, 1643, 1599,
1500, 1373, 1215, 1184 and 754; dH 7.38–7.05 (5 H, m, Ph), 6.10
(1 H, q, J 2, vinyl CH), 2.12 (3 H, d, J 2, CH3) and 1.86 (3 H,
s, CH3).
J. Chem. Soc., Perkin Trans. 1, 1998 2605
1-Phenyl-3-acetyl-4-formyl-4-methyl-1,3-diazetidin-2-one 20
Through a solution of alkene 19 (100 mg, 0.5 mmol) in 20 cm3
of CH2Cl2 was passed a stream of ozone at 278 8C until the
light blue colour persisted. The reaction mixture was flushed
with oxygen for 5 min. Me2S (150 ml, 124 mg, 2 mmol) was
added dropwise to the reaction mixture at 0 8C and then stirred
at 0 8C to room temperature for 1 h. Removal of the solvent in
vacuo gave acetamido aldehyde 20 (80 mg, 69%) after column
purification (hexane to 30% EtOAc–hexane) (Found: C, 62.47;
H, 5.16; N, 12.81. C12H12N2O3 requires C, 62.07; H, 5.17;
N, 12.07%); Mp 173–174 8C; nmax/cm
21 3000, 1807, 1741, 1691,
1599, 1512, 1317, 1047 and 756; dH 9.44 (1 H, s, CHO),
7.35–7.14 (5 H, m, Ph), 2.46 (3 H, s, COCH3) and 1.93 (3 H,
s, CH3).
Acetal 21
Through a solution of alkene 19 (50 mg, 0.25 mmol) in 10 cm3
of dry CH2Cl2 was passed a stream of ozone at 278 8C until the
blue colour persisted. The reaction was flushed with oxygen
for 5 min. Et3N (70 ml, 50 mg, 0.5 mmol) was added to the
mixture which was then warmed to room temperature and
stirred for 1 h. The reaction mixture was washed with 5% aq.
HCl and brine. Work up gave a 1 :1 mixture of aldehyde 20 and
acetal 21. Purification by column chromatography on silica
(hexane to 20% EtOAc–hexane) afforded a mixture of three
acetals as judged from its 1H NMR spectrum (15 mg, 26%). Mp
173–175 8C; nmax/cm
21 3320, 1813, 1680, 1602, 1246, 1116, 1032,
966 and 760; dH 7.32–6.95 (5 H, s, Ph), 5.85, 5.43, 4.98 (1 H, s,
acetal CHs), 2.37 (3 H, s, CH5) and 1.83 (3 H, s, CH3); m/z 250
(HRMS).
trans-Unsaturated ester 22
To a solution of aldehyde 20 (58 mg, 0.25 mmol) in 2 cm3 of dry
benzene was added Ph3P]]CHCO2Et (174 mg, 0.5 mmol) and
the mixture was stirred at room temperature for 1 h. Removal
of solvent in vacuo and purification by column chromatography
on silica (hexane to 20% EtOAc–hexane) provided unsaturated
ester 22 (60 mg, 80%). nmax/cm
21 3072, 2995, 1803, 1718, 1601,
1512, 1037, 985 and 754; dH 7.34–7.05 (5 H, m, Ph), 7.05 (1H,
d, J 16, vinyl CH), 6.34 (1 H, d, J 16, vinyl CH), 4.28–4.17 (2 H,
q, J 8, OCH2), 2.41 (3 H, s, CH3), 2.06 (3 H, s, CH3) and 1.31
(3 H, t, J 8, CH2CH3).
Saturated ester 23
To a solution of unsaturated ester 22 (60 mg, 0.2 mmol) in 5
cm3 of EtOAc was added 10% Pd/C (15 mg), the mixture was
flushed with H2 and then stirred at room temperature under
a H2 atmosphere for 4 h. The reaction mixture was filtered
through Celite. Work up afforded saturated ester 23 which was
used in the next step without further purification (60 mg, 99%).
nmax/cm
21 2900, 1780, 1720, 1680, 1330, 1240, 1160, 1100, 1060
and 750; dH 7.36–7.05 (5 H, m, Ph), 4.02 (2 H, q, J 8, OCH2),
2.85–2.28 (4 H, m, 2 × CH2), 2.41 (3 H, s, COCH3), 1.93 (3 H, s,
CH3) and 1.22 (3 H, t, J 8, CH2CH3); dC 171.61, 165.95, 145.67,
135.41, 129.29, 123.65, 115.98, 81.58, 60.47, 29.70, 27.86, 22.64,
22.25 and 13.77.
Amino alcohol 24
To a suspension of LiAlH4 (15 mg, 0.4 mmol) in 4 cm
3 of
dry diethyl ether at 0 8C was added a solution of ester 23 (30
mg, 0.1 mmol) in 1 cm3 of dry diethyl ether dropwise. The
reaction mixture was stirred for 1 h at 0 8C and quenched with
H2O (15 ml), 15% aq. NaOH (15 ml) and then H2O (45 ml). The
mixture was diluted with diethyl ether, dried with MgSO4 and
filtered through Celite. Work up and purification by column
chromatography on silica (hexane to 60% EtOAc–hexane)
afforded amino alcohol 24 (30 mg, 68%) (Found: C, 65.50;
H, 7.20; N, 12.68. C12H16N2O2 requires C, 65.45; H, 7.27;
N, 12.73%); nmax/cm
21 3312, 2932, 2876, 1755, 1600, 1505, 1392,
1059, 754 and 694; dH 7.35–6.96 (5 H, m, Ph), 3.75–3.65 (2 H,
m, OCH2), 2.15 (2 H, t, J 9, CH2), 1.85–1.54 (2 H, m, CH2)
and 1.76 (3 H, s, CH3); dC 153.99, 137.44, 129.35, 122.63,
115.54, 76.44, 61.95, 33.88, 26.25 and 24.25.
Aza-carbapenam 25
A solution of EtO2C]N]]N]CO2Et (DEAD) (15 ml, 17 mg, 0.1
mmol) in 0.5 cm3 of dry benzene was added to a solution of
amino alcohol 24 (11 mg, 0.05 mmol) and Ph3P (26 mg, 0.1
mmol) in 0.5 cm3 of dry benzene. The reaction mixture was
stirred at room temperature for 1 h. Removal of solvent in vacuo
and purification by column chromatography on silica (hexane
to 10% EtOAc–hexane) provided pure aza-carbapenam 25
(9 mg, 84%). nmax/cm
21 3053, 2970, 2878, 1774, 1601, 1504,
1386, 1261, 1165 and 754; dH 7.35–6.98 (5 H, m, Ph), 3.62–3.51
(1 H, m, CH2), 2.82–2.65 (1 H, m, CH2), 2.45–2.35 (1 H, m,
CH2), 2.15–1.92 (2 H, m, CH2), 1.78 (3 H, s, CH3) and 1.72–1.60
(1 H, m, CH2); dC 158.12, 137.61, 129.40, 123.04, 115.76, 84.17,
46.41, 32.18, 26.94 and 22.86; m/z 202 (LRMS).
4-Bromophenyl-aza-carbapenam 26
Synthesised by a protocol similar to that adopted for 25.
nmax/cm
21 2969, 2930, 2856, 1777, 1593, 1495, 1385, 1265, 1165,
1072 and 824; dH 7.42 (2 H, d, J 9, aromatic CH), 7.12 (2 H,
d, J 9, aromatic CH), 3.64–3.52 (1 H, m), 2.84–2.69 (1 H, m),
2.44–2.32 (1 H, m), 2.12–1.95 (2 H, m), 1.76 (3 H, s, CH3) and
1.75–1.64 (1 H, m).
Epoxide 29
A 50% dispersion of NaH in mineral oil (19 mg, 0.4 mmol)
under a N2 atmosphere was washed with dry hexane (2 × 1 cm
3)
to remove the oil and 0.8 cm3 of dry DMSO was added. The
mixture was heated to 70–75 8C for 30 min until the evolution
of H2 ceased and a somewhat cloudy pale yellow–grey solution
of the sodium salt was formed. The solution was cooled to
room temperature and diluted with an equal volume of dry
THF (0.8 cm3), the flask was cooled in an ice–salt bath (210 8C)
then a solution of (CH3)3S
1I2 (102 mg, 0.5 mmol) in 0.4 cm3 of
DMSO was added and stirring was continued for 10 min at
210 8C. Aldehyde 20 (23 mg, 0.1 mmol) in 0.5 cm3 of dry THF
was added to the sulfur ylide and stirred at 210 to 0 8C for
40 min. The reaction mixture was extracted with diethyl ether.
Work up and purification by column chromatography on silica
(hexane to 30% EtOAc–hexane) gave pure epoxide 29 (6 mg,
30%). nmax/cm
21 3059, 2961, 2930, 1770, 1601, 1504, 1385, 1265,
1128, 1074, 739 and 694; dH 7.35–6.98 (5 H, m, Ph), 5.20 (1 H,
s, NH), 3.31–3.26 (1 H, m, oxirane CH), 2.92–2.81 (2 H, m,
oxirane CH2) and 1.61 (3 H, s, C3); dC 153.20, 136.73, 129.35,
123.06, 115.93, 74.65, 54.10, 44.28 and 17.62; m/z 204 (LRMS).
Alcohol 30
LiAlH4 (15 mg, 0.4 mmol) and acetamido aldehyde 20 (23.2 mg,
0.1 mmol) in 5 cm3 of dry diethyl ether were stirred at 0 8C for
1 h. Purification by column chromatography on silica (hexane
to 50% EtOAc–hexane) gave alcohol 30 (6 mg, 29%). nmax/cm
21
3325, 3053, 2928, 1757, 1600, 1504, 1385, 1072, 754 and 694;
dH 7.32–6.95 (5 H, m, Ph), 5.40 (1 H, s, NH), 3.92 (2 H, q,
JAB 12, OCH2) and 1.68 (3 H, s, CH3).
Alcohol 31 and ã-lactol 32
Acetamido aldehyde 20 (232 mg, 1 mmol) was taken up in 4 cm3
of CH3OH, cooled to 0 8C and NaBH4 (152 mg, 4 mmol) added
slowly in portions and stirred for 1 h. The reaction mixture was
acidified with 5% aq. HCl to pH 4 and extracted with diethyl
ether. Work up afforded a 4 :1 mixture of g-lactol 32 and
hydroxy amide 31. Purification by column chromatography on
silica (hexane to 50% EtOAc–hexane) gave pure g-lactol 32
(103 mg, 44%) followed by alcohol 31. nmax/cm
21 (32) 3342,
2935, 1797, 1691, 1340, 1072 and 752; dH (32) 7.38–6.85 (5 H,
m, Ph), 4.28 (1H, d, J 12, OCH2), 3.76 (1 H, d, J 12, OCH2),
2.41 (3 H, s, CH3) and 1.71 (3 H, s, CH3); dH (31) 7.38–6.85 (5 H,
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m, Ph), 4.22 (1 H, d, J 12, OCH2), 3.98 (1 H, d, J 12, OCH2),
2.42 (3 H, s, CH3) and 1.87 (3 H, s, CH3); dC (mixture of 31 and
32) 167.57, 152.44, 148.58, 129.78, 120.73, 119.56, 118.21,
84.64, 61.57, 22.61 and 18.08; m/z 234 (LRMS).
Dibromo olefin 33
To a mixture of PPh3 (105 mg, 0.4 mmol) and CBr4 (66 mg,
0.2 mmol) in 1 cm3 of dry CH2Cl2 was added aldehyde 20
(23 mg, 0.1 mmol) in 0.5 cm3 of CH2Cl2 and stirred for 10 min
at 0 8C. The reaction mixture was quenched with brine and
extracted with diethyl ether (3 × 5 cm3). Work up provided
crude dibromo olefin 33 which was purified by column chrom-
atography on silica (hexane to 20% EtOAc–hexane) (12 mg,
35% unoptimised). nmax/cm
21 2926, 2855, 1802, 1695, 1599,
1512, 1367, 1315, 1244, 1163 and 748; dH 7.41–7.08 (5 H, m,
Ph), 6.91 (1 H, s, vinyl CH), 2.41 (3 H, s, CH3) and 1.99 (3 H,
s, CH3).
Hydroxy amide 34
To a stirred solution of amino alcohol 24 (33 mg, 0.15 mmol)
in 2 cm3 of dry CH2Cl2 was added PCC (130 mg, 0.6 mmol)
at 0 8C. The resulting brown solution was stirred for 2 h at
0 8C to room temperature. The reaction mixture was diluted
with 5 cm3 dry diethyl ether and filtered through Celite. Work
up and purification by column chromatography on silica
(hexane to 30% EtOAc–hexane) afforded pure hydroxy amide
34 (21 mg, 65%). Mp 130–131 8C (Found: C, 66.35; H, 6.64;
N, 13.87. C12H14N2O2 requires C, 66.02; H, 6.47; N, 12.84%);
nmax/cm
21 3383, 3055, 2924, 2852, 1771, 1601, 1504, 1388,
1263, 1170, 1078 and 739; dH 7.35–6.99 (5 H, m, Ph), 5.32
(1 H, d, J 3, NCH), 2.84 (1 H, br s, OH), 2.45–2.05 (4 H, m,
2 × CH2) and 1.85 (3 H, s, CH3); dC 154.86, 136.36, 129.39,
123.41, 115.98, 85.46, 83.46, 33.96, 29.46 and 23.55; m/z 218
(LRMS).
Benzoate 35
To a solution of aminal 34 (13 mg, 0.06 mmol) in 2 cm3 of dry
CH2Cl2 was added pyridine (48 ml, 47 mg, 0.6 mmol) and
DMAP (cat.) at 0 8C. The reaction mixture was stirred for
10 min and to this was added benzoyl chloride (34 ml, 42 mg,
0.3 mmol) and stirring continued for 2 h at 0 8C to room
temperature. The reaction mixture was diluted with sat. aq.
NH4Cl and work up gave 40 mg of crude benzoate. Purification
by column chromatography on silica (hexane to 20%
EtOAc–hexane) afforded pure benzoate 35 (12 mg, 62%). Mp
100–102 8C; dH 8.06 (2 H, d, J 6, COPh), 7.65–7.05 (8 H, m, Ph),
6.42 (1 H, d, J 3, NCHO), 2.62–1.99 (4 H, m, 2 × CH2) and 1.91
(3 H, s, CH3).
TBDMS ether 36
Amino alcohol 24 (44 mg, 0.2 mmol) was taken up in 2 cm3 of
dry CH2Cl2, cooled to 0 8C and then Et3N (420 ml, 330 mg,
3 mmol) and catalytic DMAP were added and the mixture
was stirred for 10 min. TBDMSCl (151 mg, 1 mmol) was added
and stirring continued for 1 h. The reaction mixture was diluted
with H2O and extracted with diethyl ether. Work up afforded
TBDMS ether 36 which was used as such without further
purification (60 mg, 90%). nmax/cm
21 3288, 2955, 2930, 2856,
1763, 1601, 1504, 1390, 1255, 1101 and 837; dH 7.36–6.95 (5 H,
m, Ph), 5.42 (1 H, s, NH), 3.62 (2 H, t, J 6, OCH2), 2.1 (2 H, t,
J 9, CH2), 1.75 (3 H, s, CH3), 1.85–1.46 (2 H, m, CH2), 0.88 [9
H, s, SiC(CH3)3], 0.03 (3 H, s, SiCH3) and 0.02 (3 H, s, SiCH3);
dC 153.76, 137.60, 129.26, 122.49, 115.61, 76.42, 62.48, 34.12,
26.48, 25.94, 24.34, 18.28 and 25.36.
Ester 37
A 50% dispersion of NaH in mineral oil (17 mg, 0.36 mmol)
under a N2 atmosphere was washed with dry hexane (2 × 2 cm
3)
to remove the oil, 1 cm3 of dry THF was added and the mixture
was cooled to 0 8C. A solution of TBDMS ether 36 (30 mg, 0.09
mmol) in 1 cm3 of dry THF was added and stirred for 10 min,
then BrCH2CO2Et (50 ml, 75 mg, 0.45 mmol) was added and
stirring continued for 2 h at 0 8C to room temperature. The
reaction mixture was quenched with H2O and extracted with
diethyl ether. Work up afforded TBDMS ester 37 which was
used as such for the next reaction without further purification
(37 mg, 98%). nmax/cm
21 2955, 2930, 2856, 1776, 1743, 1601,
1508, 1363, 1199, 1099, 837 and 750; dH 7.35–6.94 (5 H, m,
Ph), 4.22 (2 H, q, J 9, OCH2CH3), 4.02 (2 H, s, NCH2), 3.58
(2 H, t, J 6, SiOCH2), 2.19–2.02 (2 H, m, CH2), 1.73 (3 H, s,
CH3), 1.69–1.38 (2 H, m, CH2), 1.31 (3 H, t, J 9, OCH2CH3),
0.88 [9 H, s, Si(CH3)3], 0.01 (3 H, s, SiCH3) and 0.00 (3 H, s,
SiCH3); dC 169.02, 152.99, 137.82, 129.25, 122.17, 115.52, 81.53,
62.26, 61.33, 41.89, 32.25, 26.17, 25.89, 22.59, 18.24, 14.13 and
25.42.
Alcohol ester 38
A solution of TBDMS ester 37 (42 mg, 0.1 mmol) in 2 cm3
of dry THF was cooled to 0 8C, then tetrabutylammonium
fluoride (TBAF) (63 mg, 0.2 mmol) was added and the mixture
was stirred at 0 8C for 1 h. The reaction mixture was diluted
with brine and extracted with diethyl ether. Work up and
purification by column chromatography on silica (hexane to
60% EtOAc–hexane) afforded pure alcohol ester 38 (25 mg,
82%). nmax/cm
21 3454, 2935, 1776, 1743, 1601, 1510, 1371, 1205,
1062 and 1024; dH 7.35–6.95 (5 H, m, Ph), 4.21 (2 H, q, J 9,
OCH2CH3), 4.22 (1 H, d, J 18, NCH2), 3.77 (1 H, d, J 18,
NCH2), 3.75–3.50 (2 H, m, OCH2), 2.21–1.98 (2 H, m, CH2),
1.85–1.35 (2 H, m, CH2), 1.69 (3 H, s, CH3) and 1.28 (3 H, t, J 9,
OCH2CH3); dC 169.32, 152.99, 137.75, 129.33, 122.28, 115.37,
81.46, 61.91, 61.53, 41.78, 32.07, 25.91, 22.29 and 14.09.
Aldehyde ester 39
Alcohol ester 38 (40 mg, 0.13 mmol) was taken up in 2 cm3
of dry CH2Cl2 and cooled to 0 8C, PCC (56 mg, 0.26 mmol)
was added and the mixture was stirred at 0 8C to room tem-
perature for 2 h. The reaction mixture was diluted with distilled
diethyl ether and filtered through Celite. Removal of solvent in
vacuo and purification by column chromatography on silica
(hexane to 40% EtOAc–hexane) afforded aldehyde ester 39
(30 mg, 76%). nmax/cm
21 2976, 2932, 1774, 1745, 1601, 1508,
1369, 1203 and 1093; dH 9.74 (1 H, s, CO), 7.36–6.95 (5 H, m,
Ph), 4.20 (2 H, q, J 9, OCH2), 4.12 (1 H, d, J 18, NCH), 3.79
(1 H, d, J 18, NCH), 2.98–2.76 (1 H, m, CH2), 2.42–2.04 (3 H,
m, CH2), 1.75 (3 H, s, CH3) and 1.28 (3 H, t, J 9, OCH2CH3);
dC 200.66, 168.91, 152.77, 137.88, 129.45, 122.58, 115.34, 80.48,
61.51, 41.67, 31.39, 27.71, 21.99 and 14.09.
Aza-carbacephem 40
A 50% dispersion of NaH in mineral oil (5 mg, 0.12 mmol)
in 0.5 cm3 of dry THF was taken in a dry two neck flask
and cooled to 0 8C. Aldehyde ester 39 (9 mg, 0.03 mmol) in
0.5 cm3 of dry THF was added slowly and stirred for 45 min at
0 8C. The reaction mixture was diluted with diethyl ether and
filtered through Celite. Removal of solvent in vacuo gave 5 mg
of crude aza-carbacephem 40 which was purified by column
chromatography on silica (hexane to 20% EtOAc–hexane)
(3 mg, 35%). nmax/cm
21 3021, 2928, 1784, 1732, 1601, 1508, 1373
and 1217; dH 7.36–6.98 (5 H, m, Ph), 6.34 (1 H, dd, J 6, 3, vinyl
CH), 4.42–4.36 (2 H, m, OCH2), 2.55–1.76 (4 H, m, 2 × CH2),
1.66 (3 H, s, CH3) and 1.38 (3 H, t, J 9, CH3); dC 162.48, 149.39,
136.65, 129.90, 129.37, 122.85, 118.82, 115.96, 74.82, 61.46,
31.79, 21.13, 20.89 and 14.18; m/z 286 (LRMS).
â-Hydroxy ester 42
A 50% dispersion of NaH in mineral oil (7 mg, 0.16 mmol) was
taken up in 1 cm3 of dry THF and cooled to 0 8C. A solution of
aldehyde ester 39 (12 mg, 0.04 mmol) in 0.5 cm3 of dry THF
was added and stirred at 0 8C for 20 min. The reaction mixture
was diluted with distilled diethyl ether and filtered through
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Celite. Removal of solvent in vacuo and purification by column
chromatography on silica (hexane to 20% EtOAc–hexane)
afforded pure b-hydroxy ester 42 (7 mg, 60%). nmax/cm
21 3441,
3059, 2934, 1774, 1743, 1601, 1508, 1361, 1199, 1059 and 752;
dH 7.35–6.95 (5 H, m, Ph), 4.54 (1 H, d, J 2, NCH), 4.35–4.12
(3 H, m, OCH2CH3 and CHOH), 3.10 (1 H, br s, OH), 2.64–
2.45 (2 H, m, CH2), 2.12–1.62 (2 H, m, CH2), 1.78 (3 H, s, CH3)
and 1.30 (3 H, t, J 9, OCH2CH3); dC 170.16, 154.21, 137.01,
129.28, 122.37, 115.82, 76.06, 66.38, 61.54, 60.28, 28.19, 24.35,
23.56 and 14.12; m/z 304 (LRMS).
Aza-carbacepham 47
To a solution of unsaturated ester 40 (7 mg, 0.025 mmol) in
2 cm3 of EtOAc was added 10% Pd/C (5 mg), the mixture
was flushed with H2 and then stirred at room temperature
under a H2 atmosphere for 4 h. The reaction mixture was
filtered through Celite. Work up afforded 6 mg of crude
aza-carbacepham 47 which was purified by column chromato-
graphy on silica (hexane to 20% EtOAc–hexane) (6 mg, 86%).
nmax/cm
21 2936, 2863, 1771, 1732, 1601, 1508, 1354, 1194 and
752; dH 7.35–6.95 (5 H, m, Ph), 4.59 (1 H, dd, J 8, 4, NCH),
4.28–4.12 (2 H, m, OCH2), 2.28–1.55 (4 H, m, 2 × CH2), 1.71
(3 H, s, CH3) and 1.30 (3 H, t, J 9, CH3); dC 171.91, 153.29,
137.19, 122.29, 115.80, 61.25, 51.87, 35.16, 26.87, 23.33, 17.13
and 14.17; m/z 288 (LRMS).
3-Hydroxy-aza-carbacephem 48
b-Hydroxy ester 42 (12 mg, 0.04 mmol) in 1 cm3 of acetone
was cooled to 0 8C, Jones reagent (100 ml, 0.8 mmol, 8 )
was added and stirring continued for 2 h at 0 8C to room
temperature. The reaction mixture was diluted with brine and
extracted with diethyl ether. Work up provided a 1 :1 mixture
of keto–enol isomers which when left at room temperature for
2 days afforded enol 48 which was purified by chromatography
on silica (hexane to 40% EtOAc–hexane) (11 mg, 88%). nmax/
cm21 3418, 2924, 2855, 1807, 1749, 1694, 1601, 1506, 1352, 1256
and 1157; dH 11.64 (1 H, s, enol H), 7.42–7.06 (5 H, m, Ph), 4.44
(2 H, q, J 9, OCH2), 2.94–2.05 (4 H, m, 2 × CH2), 2.00 (3 H,
s, CH3), 1.66 (3 H, s, CH3) and 1.42 (3 H, t, J 9, OCH2CH3);
m/z 208 (LRMS).
Methyl enol ether 49
Diazomethane was generated by adding N-nitroso-N-methyl-
urea (200 mg, 2 mmol) to a solution of 50% aq. KOH (20 cm3)
in 10 cm3 of diethyl ether at 0 8C, the solution was left for a few
minutes till the yellow colour developed. The diethyl ether layer
was distilled and CH2N2 was bubbled through a solution of
enol 48 (12 mg, 0.04 mmol) in 10 cm3 of distilled diethyl ether at
0 8C. When the solution turned yellow it was slowly warmed to
room temperature and left to dry. The crude methyl enol ether
49 was purified by column chromatography on silica (hexane to
20% EtOAc–hexane) (8 mg, 63%). nmax/cm
21 2938, 1807, 1742,
1601, 1510, 1445, 1352, 1257, 1091, 754 and 692; dH 7.42–7.12
(5 H, m, Ph), 4.45 (2 H, q, J 9, OCH2), 3.60 (3 H, s, OCH3),
2.90–2.36 (4 H, m, 2 × CH2), 2.00 (3 H, s, CH3) and 1.42 (3 H,
t, J 9, CH3); dC 172.06, 159.54, 135.07, 129.69, 129.35, 124.56,
116.54, 115.96, 82.54, 63.17, 51.87, 30.21, 27.75, 22.45, 13.85;
m/z 317 (LRMS).
Phenolic alcohol 52
Through a solution of alkene (100 mg, 0.5 mmol) in 20 cm3 of
CH2Cl2 was passed a stream of ozone at 278 8C until the light
blue colour persisted. The reaction mixture was flushed with
oxygen for 5 min, NaBH4 (76 mg, 2 mmol) added at 0 8C and
stirring continued for 1 h at 0 8C. The reaction mixture was
acidified with 5% aq. HCl to pH 4 and extracted with diethyl
ether. Work-up and purification by column chromatography on
silica (hexane to 50% EtOAc–hexane) afforded pure phenolic
alcohol 52 (50 mg, 40%). dH 7.42–6.88 (5 H, m, Ph), 4.42 (1 H,
d, J 12, OCH2), 3.88 (1 H, d, J 12, OCH2), 2.48 (3 H, s, CH3),
1.85 (3 H, s, CH3); m/z 250 (LRMS).
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